NPM1 EXON 11 MUTATION

CI-VAR-00000879Explore in graph →CIViC 86

Curated evidence

Evidence by cancer (31 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–31 of 31 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia29
NPM1 EXON 11 MUTATION	(diagnostic)	Diagnostic	A	Supports Positive	5	accepted	EID116 AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recomm… (full text at CIViC) PMID 19357394 · Vardiman et al., 2009 · Open in CIViC	civic
NPM1 EXON 11 MUTATION	(diagnostic)	Diagnostic	B	Supports Negative	4	accepted	EID111 NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia. PMID 16076867 · Schnittger et al., 2005 · Open in CIViC	civic
NPM1 EXON 11 MUTATION	(diagnostic)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Acute Myeloid Leukemia with NPM1 Mutation2
NPM1 EXON 11 MUTATION	Revumenib	Predictive	B	Supports Sensitivity Response	4	submitted	EID13286 In the phase 2 portion of AUGMENT-101 (NCT04065399), an open-label, single-arm, multicentre study, patients with relapsed or refractory NPM1-mutated acute myeloid leukaemia received the oral menin inh… (full text at CIViC) PMID 40332046 · Arellano et al., 2025 · Open in CIViC	civic
NPM1 EXON 11 MUTATION	Ziftomenib	Predictive	B	Supports Sensitivity Response	4	submitted	EID13285 In the registration-enabling phase II portion of KOMET-001 (NCT04067336), an open-label, single-arm, multicentre trial, 92 adults with relapsed or refractory NPM1-mutated acute myeloid leukaemia (NPM1… (full text at CIViC) PMID 40997296 · Wang et al., 2025 · Open in CIViC	civic